236 related articles for article (PubMed ID: 10340911)
1. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
2. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
3. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
4. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
5. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
6. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
8. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
9. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
11. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
13. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
15. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Avenoso A; Facciolà G; Scordo MG; Spina E
Ther Drug Monit; 1999 Oct; 21(5):577-9. PubMed ID: 10519458
[TBL] [Abstract][Full Text] [Related]
16. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
18. A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.
Vengurlekar SS; Heitkamp J; McCush F; Velagaleti PR; Brisson JH; Bramer SL
J Pharm Biomed Anal; 2002 Aug; 30(1):113-24. PubMed ID: 12151071
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CYP2D6 activity by bupropion.
Kotlyar M; Brauer LH; Tracy TS; Hatsukami DK; Harris J; Bronars CA; Adson DE
J Clin Psychopharmacol; 2005 Jun; 25(3):226-9. PubMed ID: 15876900
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]